Gilead Strikes Another Deal

Gilead Sciences (GILD) has continues to strike back at after Express Scripts (ESRX) made AbbVie’s (ABBV) hepatitis-C drug its treatment of choice. Today, Aetna, the third-largest U.S. health insurer, said it has negotiated a discount with Gilead for its hepatitis C treatment and will offer it as the preferred choice to its nearly 20 million [...]